[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628557":3},{"organization":4,"outcomesModule":7,"designInfo":34,"detailedDescription":33,"studyPopulation":33,"armGroups":46,"interventions":67,"overallOfficials":79,"centralContacts":83,"locations":89,"responsibleParty":455,"collaborators":33,"id":457,"slug":458,"hasResults":459,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":33,"eligibilityCriteria":463,"healthyVolunteers":459,"sex":464,"minAge":465,"maxAge":466,"enrollmentInfo":467,"targetDuration":33,"studyType":470,"phases":471,"briefSummary":473,"conditions":474,"keywords":33,"overallStatus":92,"whyStopped":33,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":486},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":33},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12","The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: Endoscopic subscore (ES), scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); Stool frequency subscore (SFS), scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and rectal bleeding subscore (RBS), scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical Remission is defined as an ES of 0 or 1 with no friability, RBS of 0, and SFS of 0 or 1 and not greater than the baseline SFS.","Week 12",[14,18,21,24,27,30],{"measure":15,"description":16,"timeFrame":17},"Percentage of Participants With One or More Adverse Events (AEs)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experience an AE will be reported.","Up to approximately 12 months",{"measure":19,"description":20,"timeFrame":17},"Percentage of Participants Who Discontinued Study Intervention Due to an AE","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported.",{"measure":22,"description":23,"timeFrame":12},"Percentage of Participants Achieving Clinical Response Per MMS at Week 12","The MMS is a composite score of UC disease activity on a scale of increasing severity from 0-9, calculated by summing three subscores: ES, scored on a scale of increasing severity from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration); SFS, scored on a scale of increasing frequency from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant); and RBS, scored on a scale of increasing severity from 0 (no blood seen) to 3 (blood alone passed). Clinical response is defined as an MMS reduction of 2 or more points and 30% or more from baseline, plus a reduction of 1 or more points in RBS or an absolute RBS of 0 or 1.",{"measure":25,"description":26,"timeFrame":12},"Percentage of Participants With Endoscopic Improvement at Week 12","Endoscopic improvement is defined as ES of 0 or 1 with no friability. The ES measures UC severity based on endoscopy on a 0-3 scale of increasing severity.",{"measure":28,"description":29,"timeFrame":12},"Percentage of Participants Achieving Clinical Remission Per Partial Modified Mayo Score (pMMS) at Week 12","pMMS is a composite score of UC disease activity on a scale of increasing severity from 0-6, calculated by summing two subscores: SFS, scored from 0 (normal number of stools) to 3 (≥5 stools more than normal per day for the participant) and RBS, scored from 0 (no blood seen) to 3 (blood alone passed). Clinical remission per pMMS is defined as an RBS of 0 and SFS of less than or equal to 1.",{"measure":31,"description":32,"timeFrame":12},"Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement (HEMI) at Week 12","HEMI is defined as a Geboes score of 3.1 or less and ES of 0 or 1 with no friability. The Geboes score is a histologic grading system for inflammation in UC with scores ranging from 0 to 5.4, with higher scores indicating more severe inflammation. ES measures UC severity based on endoscopy, scored from 0 (normal or inactive disease) to 3 (severe disease, such as spontaneous bleeding or ulceration).",null,{"allocation":35,"interventionModel":36,"interventionModelDescription":37,"primaryPurpose":38,"observationalModel":33,"timePerspective":33,"maskingInfo":39},"RANDOMIZED","PARALLEL","Participants in Period 1 will have parallel assignment.","TREATMENT",{"masking":40,"maskingDescription":41,"whoMasked":42},"TRIPLE","Period 1 is double-blind. Period 2 and Period 3 are open-label.",[43,44,45],"PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR",[47,53,59,63],{"label":48,"type":49,"description":50,"interventionNames":51},"Period 1: MK-8690","EXPERIMENTAL","Participants will receive MK-8690 via subcutaneous injection for 12 weeks.",[52],"Drug: MK-8690",{"label":54,"type":55,"description":56,"interventionNames":57},"Period 1: Placebo","PLACEBO_COMPARATOR","Participants will receive placebo via subcutaneous injection for 12 weeks.",[58],"Other: Placebo",{"label":60,"type":49,"description":61,"interventionNames":62},"Period 2: MK-8690","Participants who do not respond to treatment in Period 1 (regardless of treatment assignment in Period 1) will receive MK-8690 via subcutaneous injection for 12 weeks.",[52],{"label":64,"type":49,"description":65,"interventionNames":66},"Period 3: MK-8690","Participants who respond to treatment in either Period 1 or Period 2 will receive additional MK-8690 via subcutaneous injection for up to approximately 42 weeks.",[52],[68,75],{"type":69,"name":70,"description":71,"armGroupLabels":72,"otherNames":73},"DRUG","MK-8690","Solution for subcutaneous injection",[48,60,64],[74],"PRA052",{"type":76,"name":77,"description":71,"armGroupLabels":78,"otherNames":33},"OTHER","Placebo",[54],[80],{"name":81,"affiliation":5,"role":82},"Medical Director","STUDY_DIRECTOR",[84],{"name":85,"role":86,"phone":87,"phoneExt":33,"email":88},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[90,108,120,133,145,158,170,183,196,209,222,237,250,258,271,286,301,310,325,338,353,366,375,388,402,415,427,442],{"facility":91,"status":92,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":103,"contacts":104},"Clinnova Research ( Site 1042)","RECRUITING","Anaheim","California","92805","United States","US",{"type":99,"coordinates":100},"Point",[101,102],-117.9145,33.83529,{"lat":102,"lon":101},[105],{"name":106,"role":86,"phone":107,"phoneExt":33,"email":33},"Study Coordinator","949-889-0249",{"facility":109,"status":92,"city":110,"state":94,"zip":111,"country":96,"countryCode":97,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"Southern California Research Center ( Site 1044)","Coronado","92118",{"type":99,"coordinates":113},[114,115],-117.18309,32.68589,{"lat":115,"lon":114},[118],{"name":106,"role":86,"phone":119,"phoneExt":33,"email":33},"619-522-0330",{"facility":121,"status":92,"city":122,"state":123,"zip":124,"country":96,"countryCode":97,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Peak Gastroenterology Associates ( Site 1052)","Colorado Springs","Colorado","80907",{"type":99,"coordinates":126},[127,128],-104.82136,38.83388,{"lat":128,"lon":127},[131],{"name":106,"role":86,"phone":132,"phoneExt":33,"email":33},"719-636-1201",{"facility":134,"status":92,"city":135,"state":123,"zip":136,"country":96,"countryCode":97,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"South Denver Gastroenterology, PC ( Site 1068)","Englewood","80113",{"type":99,"coordinates":138},[139,140],-104.98776,39.64777,{"lat":140,"lon":139},[143],{"name":106,"role":86,"phone":144,"phoneExt":33,"email":33},"303-406-4288",{"facility":146,"status":92,"city":147,"state":148,"zip":149,"country":96,"countryCode":97,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Nature Coast Clinical Research ( Site 1045)","Inverness","Florida","34452",{"type":99,"coordinates":151},[152,153],-82.33037,28.83582,{"lat":153,"lon":152},[156],{"name":106,"role":86,"phone":157,"phoneExt":33,"email":33},"352-341-2100",{"facility":159,"status":92,"city":160,"state":148,"zip":161,"country":96,"countryCode":97,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Research Associates of South Florida - Miami - Southwest 8th Street ( Site 1072)","Miami","33134",{"type":99,"coordinates":163},[164,165],-80.19366,25.77427,{"lat":165,"lon":164},[168],{"name":106,"role":86,"phone":169,"phoneExt":33,"email":33},"786-476-8790",{"facility":171,"status":92,"city":172,"state":173,"zip":174,"country":96,"countryCode":97,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Gastroenterology Associates of Central Georgia ( Site 1060)","Macon","Georgia","31201",{"type":99,"coordinates":176},[177,178],-83.6324,32.84069,{"lat":178,"lon":177},[181],{"name":106,"role":86,"phone":182,"phoneExt":33,"email":33},"478-464-2600",{"facility":184,"status":92,"city":185,"state":186,"zip":187,"country":96,"countryCode":97,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"University of Kansas Medical Center ( Site 1077)","Kansas City","Kansas","66160",{"type":99,"coordinates":189},[190,191],-94.62746,39.11417,{"lat":191,"lon":190},[194],{"name":106,"role":86,"phone":195,"phoneExt":33,"email":33},"913-588-6019",{"facility":197,"status":92,"city":198,"state":199,"zip":200,"country":96,"countryCode":97,"cosmosGeoPoint":201,"geoPoint":205,"contacts":206},"Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073)","New Orleans","Louisiana","70112",{"type":99,"coordinates":202},[203,204],-90.07507,29.95465,{"lat":204,"lon":203},[207],{"name":106,"role":86,"phone":208,"phoneExt":33,"email":33},"504-988-5110",{"facility":210,"status":92,"city":211,"state":212,"zip":213,"country":96,"countryCode":97,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"BVL Research - Kansas ( Site 1054)","Liberty","Missouri","64068",{"type":99,"coordinates":215},[216,217],-94.41912,39.24611,{"lat":217,"lon":216},[220],{"name":106,"role":86,"phone":221,"phoneExt":33,"email":33},"816-222-4241",{"facility":223,"status":92,"city":224,"state":225,"zip":226,"country":227,"countryCode":228,"cosmosGeoPoint":229,"geoPoint":233,"contacts":234},"Servicios de Salud IPS Suramericana S.A.S. - IPS Sura Industriales Medellín ( Site 1163)","Medellín","Antioquia","050001","Colombia","CO",{"type":99,"coordinates":230},[231,232],-75.57151,6.245,{"lat":232,"lon":231},[235],{"name":106,"role":86,"phone":236,"phoneExt":33,"email":33},"+57 3134673355",{"facility":238,"status":92,"city":239,"state":240,"zip":241,"country":227,"countryCode":228,"cosmosGeoPoint":242,"geoPoint":246,"contacts":247},"Clinica de la Costa S.A.S. ( Site 1161)","Barranquilla","Atlántico","080020",{"type":99,"coordinates":243},[244,245],-74.78132,10.96854,{"lat":245,"lon":244},[248],{"name":106,"role":86,"phone":249,"phoneExt":33,"email":33},"+573006528529",{"facility":251,"status":92,"city":252,"state":253,"zip":254,"country":227,"countryCode":228,"cosmosGeoPoint":33,"geoPoint":33,"contacts":255},"Fundacion Santa Fe de Bogota ( Site 1165)","Bogota","Cundinamarca","110111",[256],{"name":106,"role":86,"phone":257,"phoneExt":33,"email":33},"+57 3165243088",{"facility":259,"status":92,"city":260,"state":261,"zip":262,"country":227,"countryCode":228,"cosmosGeoPoint":263,"geoPoint":267,"contacts":268},"Fundación Valle del Lili ( Site 1162)","Cali","Valle del Cauca Department","760032",{"type":99,"coordinates":264},[265,266],-76.5199,3.43054,{"lat":266,"lon":265},[269],{"name":106,"role":86,"phone":270,"phoneExt":33,"email":33},"+573146824542",{"facility":272,"status":92,"city":273,"state":274,"zip":275,"country":276,"countryCode":277,"cosmosGeoPoint":278,"geoPoint":282,"contacts":283},"Centre Hospitalier Dr Schaffner ( Site 1288)","Lens","Pas-de-Calais","62300","France","FR",{"type":99,"coordinates":279},[280,281],2.82791,50.43302,{"lat":281,"lon":280},[284],{"name":106,"role":86,"phone":285,"phoneExt":33,"email":33},"+33321691306",{"facility":287,"status":92,"city":288,"state":289,"zip":290,"country":291,"countryCode":292,"cosmosGeoPoint":293,"geoPoint":297,"contacts":298},"Evangelismos General Hospital of Athens ( Site 1362)","Athens","Attica","10676","Greece","GR",{"type":99,"coordinates":294},[295,296],23.72784,37.98376,{"lat":296,"lon":295},[299],{"name":106,"role":86,"phone":300,"phoneExt":33,"email":33},"+306977617000",{"facility":302,"status":92,"city":288,"state":289,"zip":303,"country":291,"countryCode":292,"cosmosGeoPoint":304,"geoPoint":306,"contacts":307},"THORACIC GENERAL HOSPITAL OF ATHENS \"I SOTIRIA\" ( Site 1361)","115 27",{"type":99,"coordinates":305},[295,296],{"lat":296,"lon":295},[308],{"name":106,"role":86,"phone":309,"phoneExt":33,"email":33},"+302107763359",{"facility":311,"status":92,"city":312,"state":313,"zip":314,"country":315,"countryCode":316,"cosmosGeoPoint":317,"geoPoint":321,"contacts":322},"Radboudumc ( Site 1650)","Nijmegen","Gelderland","6525 GA","Netherlands","NL",{"type":99,"coordinates":318},[319,320],5.85278,51.8425,{"lat":320,"lon":319},[323],{"name":106,"role":86,"phone":324,"phoneExt":33,"email":33},"0031 24-3619190",{"facility":326,"status":92,"city":327,"state":328,"zip":329,"country":315,"countryCode":316,"cosmosGeoPoint":330,"geoPoint":334,"contacts":335},"Amsterdam UMC, locatie VUmc ( Site 1651)","Amsterdam","North Holland","1081 HZ",{"type":99,"coordinates":331},[332,333],4.88969,52.37403,{"lat":333,"lon":332},[336],{"name":106,"role":86,"phone":337,"phoneExt":33,"email":33},"020-4446630",{"facility":339,"status":92,"city":340,"state":341,"zip":342,"country":343,"countryCode":344,"cosmosGeoPoint":345,"geoPoint":349,"contacts":350},"PROMED P. LACH R. GLOWACKI SP. J. ( Site 1447)","Krakow","Lesser Poland Voivodeship","31-513","Poland","PL",{"type":99,"coordinates":346},[347,348],19.93658,50.06143,{"lat":348,"lon":347},[351],{"name":106,"role":86,"phone":352,"phoneExt":33,"email":33},"+48124111398",{"facility":354,"status":92,"city":355,"state":356,"zip":357,"country":343,"countryCode":344,"cosmosGeoPoint":358,"geoPoint":362,"contacts":363},"EB Group Sp. Z o.o. Centrum Zdrowia MDM ( Site 1449)","Warsaw","Masovian Voivodeship","00-189",{"type":99,"coordinates":359},[360,361],21.01178,52.22977,{"lat":361,"lon":360},[364],{"name":106,"role":86,"phone":365,"phoneExt":33,"email":33},"+48783959687",{"facility":367,"status":92,"city":355,"state":356,"zip":368,"country":343,"countryCode":344,"cosmosGeoPoint":369,"geoPoint":371,"contacts":372},"Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś ( Site 1448)","04-501",{"type":99,"coordinates":370},[360,361],{"lat":361,"lon":360},[373],{"name":106,"role":86,"phone":374,"phoneExt":33,"email":33},"+48507091469",{"facility":376,"status":92,"city":377,"state":378,"zip":379,"country":343,"countryCode":344,"cosmosGeoPoint":380,"geoPoint":384,"contacts":385},"Twoja Przychodnia - Szczeciskie Centrum Medyczne ( Site 1450)","Szczecin","West Pomeranian Voivodeship","71-434",{"type":99,"coordinates":381},[382,383],14.55302,53.42894,{"lat":383,"lon":382},[386],{"name":106,"role":86,"phone":387,"phoneExt":33,"email":33},"+48914332919",{"facility":389,"status":92,"city":390,"state":391,"zip":392,"country":393,"countryCode":33,"cosmosGeoPoint":394,"geoPoint":398,"contacts":399},"Wonju Severance Christian Hospital ( Site 1602)","Wŏnju","Kang-won-do","26426","South Korea",{"type":99,"coordinates":395},[396,397],127.94528,37.35139,{"lat":397,"lon":396},[400],{"name":106,"role":86,"phone":401,"phoneExt":33,"email":33},"+82 33 741 0505",{"facility":403,"status":92,"city":404,"state":405,"zip":406,"country":393,"countryCode":33,"cosmosGeoPoint":407,"geoPoint":411,"contacts":412},"Korea University Ansan Hospital ( Site 1603)","Ansan-si","Kyonggi-do","15355",{"type":99,"coordinates":408},[409,410],126.82194,37.32361,{"lat":410,"lon":409},[413],{"name":106,"role":86,"phone":414,"phoneExt":33,"email":33},"+82314127674",{"facility":416,"status":92,"city":417,"state":33,"zip":418,"country":393,"countryCode":33,"cosmosGeoPoint":419,"geoPoint":423,"contacts":424},"Kangbuk Samsung Hospital ( Site 1601)","Seoul","03181",{"type":99,"coordinates":420},[421,422],126.9784,37.566,{"lat":422,"lon":421},[425],{"name":106,"role":86,"phone":426,"phoneExt":33,"email":33},"+82-2-2001-8556",{"facility":428,"status":92,"city":429,"state":430,"zip":431,"country":432,"countryCode":433,"cosmosGeoPoint":434,"geoPoint":438,"contacts":439},"Fairfield General Hospital ( Site 1524)","Bury","Lancashire","BL9 7TD","United Kingdom","UK",{"type":99,"coordinates":435},[436,437],-2.3,53.6,{"lat":437,"lon":436},[440],{"name":106,"role":86,"phone":441,"phoneExt":33,"email":33},"+4401617783879",{"facility":443,"status":92,"city":444,"state":445,"zip":446,"country":432,"countryCode":433,"cosmosGeoPoint":447,"geoPoint":451,"contacts":452},"Huddersfield Royal Infirmary ( Site 1522)","Huddersfield","York","HD3 3EA",{"type":99,"coordinates":448},[449,450],-1.78416,53.64904,{"lat":450,"lon":449},[453],{"name":106,"role":86,"phone":454,"phoneExt":33,"email":33},"+4401484355434",{"type":456,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100628557","phase-2-a-study-to-evaluate-efficacy-and-safety-of-mk-8690-in-participants-with-moderately-to-severely-active-ulcerative-colitis-mk-8690-002-100628557",false,"NCT07463183","A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)","A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants With Moderately to Severely Active Ulcerative Colitis","The main inclusion criteria include but are not limited to the following:\n\n* Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization\n* Has moderately to severely active UC\n* Has a weight ≥40 kg\n* Satisfies at least 1 of the criteria: Has had an inadequate response or loss of response to 1 or more protocol-specified treatments; protocol specified corticosteroid dependence; has been intolerant to 1 or more protocol-specified UC treatments\n* Is on treatment with any protocol-specified drugs during the study and meets drug stabilization requirements, as applicable\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of Crohn's Disease (CD) or indeterminate colitis (inflammatory bowel disease (IBD)-undefined) or other types of colitis or enteritis that may confound efficacy assessment\n* Has a current diagnosis of fulminant colitis and\u002For toxic megacolon\n* Has UC limited to the rectum\n* Has a current or impending need for colostomy or ileostomy\n* Has had a total proctocolectomy or partial colectomy\n* Has UC exacerbation requiring hospitalization within 2 weeks before Screening\n* Has any active infection as specified in the protocol\n* Is known to be infected with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)\n* Has evidence of active tuberculosis (TB) or meets TB exclusionary parameters\n* Has a history of cancer (except fully treated nonmelanoma skin cell cancers or cervical carcinoma in situ after complete surgical removal) and is disease free for \\\u003C5 years before Randomization or has a history of colorectal cancer at any time\n* Has prior or current evidence of definite colonic dysplasia except for low-grade dysplasia that has been completely removed\n* Has had major surgery within 3 months before Screening or has a major surgery (ie, surgical procedure requiring general anesthesia) planned during the study\n* Has received protocol-specified prohibited medications","ALL","18 Years","75 Years",{"count":468,"type":469},100,"ESTIMATED","INTERVENTIONAL",[472],"PHASE2","The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.",[475,476],"Colitis Ulcerative","Ulcerative Colitis","2026-08-20",{"date":479,"type":480},"2026-08-21","ACTUAL",{"date":482,"type":480},"2026-03-24",{"date":484,"type":469},"2028-12-21",{"name":5,"class":6},28]